Yantacaw Capital
Venture fund · from SEC filings

Lav Biosciences Fund IV, L.P.

Lilly Asia Ventures · adviser of record: Lav Advanced Management Company Limited · 2016 vintage

Lav Biosciences Fund IV, L.P. is a 2016 venture fund managed by Lilly Asia Ventures, with $450mm raised (Form D, amount sold). It reported $537mm in gross assets at year-end 2025, 1.19x its size, against a peak of $1.43bn in 2020.

Latest value held
$537mm year-end 2025
Peak
$1.43bn year-end 2020
Fund size
$450mm Form D, amount sold
Held vs. size
1.19x peak 3.18x

Value held by year-end

$500mm$1bn$1.5bn2016201720182019202020212022202320242025

Gross asset value reported on Form ADV at each year-end. Dashed line: fund size. Open in the Fund Tracker

Year-endGross assets÷ sizeChange
2025$537mm1.19x-56% over 2 yrs
2023$1.22bn2.70x+3%
2022$1.19bn2.63x-12%
2021$1.35bn3.00x-6%
2020$1.43bn3.18x+77%
2019$809mm1.80x+100%
2018$405mm0.90x-10%
2017$450mm1.00x-2%
2016$459mm1.02x–

What public pensions report

InvestorAs ofCommitmentCash back (DPI)Total (TVPI)Still held
CalSTRS2025-06-30$40mm0.85x1.88x1.04x

Latest report from each pension, as multiples of paid-in capital. Michigan reports dollar value held, shown under Still held.

Other funds from Lilly Asia Ventures

All Lilly Asia Ventures funds

About these numbers

Gross asset value is what the manager reports holding in the fund at each fiscal year-end, on SEC Form ADV, Schedule D. It includes the GP’s own commitment and is before carried interest, so it is not the LPs’ net return, and it does not show cash already distributed. A fall in value can mean distributions, markdowns or both. Fund size is the amount sold reported on Form D, which for some funds reflects only a first close. Private fund ID 805-2293281418. Data updated October 13, 2026.

Is this your fund?

Spot an error and email a correction. Facing DPI pressure? See how distribution financing works.